Q1. Does your trust treat the following conditions?
a. Advanced oesophageal cancer
b. Advanced gastric cancer
c. In case you do not treat either of the above conditions, which other trust do you refer these patients to?
Q2. Please provide the total number of patients treated in the last 6 months for
a. Oesophageal cancer (any type)
b. Oesophageal adenocarcinoma
c. Oesophageal squamous cell carcinoma
d. Unresectable oesophageal squamous cell carcinoma
e. Gastric cancer (any type)
f. HER2 negative or HER2 untested gastric cancer
Q3. For oesophageal squamous cell carcinoma only, how many patients were treated in the past 6 months with:
a. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
b. Any other systemic anti-cancer therapy
c. Palliative care only
Q4. For gastric cancer only, how many patients were treated in the past 6 months with:
a. CapeOx (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Any other systemic anti-cancer therapy
d. Palliative care only
Q5. Does your trust participate in any ongoing clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Q6. Does your trust participate in any ongoing clinical trials for the treatment of gastric cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Download response Oesophageal and gastric cancer. 110821.docx